Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 8, Issue 9, Pages 1281-1290Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.4874
Keywords
IL-6; chronic lung diseases
Categories
Funding
- National Institute of Health [PO1 AI045666, AI094027, P30 RR031158]
- NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR031158] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI094027, P01AI045666] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The incidence and severity of chronic lung diseases is growing and affects between 100 and 150 million people worldwide and is associated with a significant rate of mortality. Unfortunately, the initial cause that triggers most chronic lung diseases remains unknown and current available therapies only ameliorate, but do not cure the disease. Thus, there is a need for identification of new targets and development of novel therapies especially for those most severely affected. IL-6, like other inflammatory cytokines, has been shown to be elevated in different lung diseases, but it was considered a byproduct of ongoing inflammation in the lung. However, recent studies support a dissociation of IL-6 from inflammation in the lung and suggest that this cytokine plays an active role in pathogenesis of asthma and, in all likelihood, COPD. IL-6 may therefore be a germane target for treatment of these and other chronic lung disease. Here, we provide an overview of the studies in mouse models and human patients that provide support for the involvement of IL-6 in lung diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available